Overview

Study Evaluating the Efficacy of DVS-233 in Fibromyalgia

Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine if DVS-233 is safe and effective in the treatment of pain and other symptoms of fibromyalgia syndrome.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Criteria
Inclusion Criteria:

- Fibromyalgia according to 1990 American College of Rheumatology (ACR) criteria

Exclusion Criteria:

- Other painful conditions that may make results difficult to interpret.

- Treatment with other drugs for fibromyalgia with 14 days of study start or during the
study.